By HealthDay Staff HealthDay ReporterWEDNESDAY, May 27, 2026 (HealthDay News) — A new study suggests GLP-1 medications may ...

GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week at the American Society of Clinical Oncology’s annual meeting.

GLP-1 drugs commonly used for weight loss and diabetes decreased the risk of cancer spreading in patients with several ...

A Cleveland Clinic study finds Ozempic-style GLP-1 drugs may significantly slow the spread of several obesity-related cancers ...

GLP-1 medications were initially developed and prescribed to help manage blood sugar in people with Type 2 diabetes ...

A Cleveland Clinic study suggests GLP-1 weight loss drugs may help slow the spread of some obesity-related cancers.

Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related ...

Primary care practitioners serve a critical role in optimizing clinical outcomes for adults with T2DM by evaluating underlying mechanisms, treatment efficacy, medication safety profiles, and ...

GLP-1 drugs, such as Ozempic and Wegovy, may slow down the spread of obesity-related cancers, according to researchers ...

—Study findings highlight the need for improved recommendations of guideline-directed therapies and support the consideration of dual therapy in appropriately selected high-risk patients. In a study ...

Popular weight loss drugs may be doing more than just helping people shed kilos. GLP-1 medications such as semaglutide ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors were linked to lower risks for CKD and AKI but greater risks for albuminuria vs. GLP-1s. Risk ...